Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair

Psychopharmacology

Volumn 222, Issue 2, 2012, Pages 203-214

  Goeldner, Celia ^a   Spooren, Will ^a   Wichmann, Jürgen ^a   Prinssen, Eric P ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Anxiety; Anxiolytic; Benzodiazepines; Conflict tests; Depression; N OFQ; NOP receptor; ORL1

Indexed keywords

8 (2,3,3A,4,5,6 HEXAHYDRO 1H PHENALEN 1 YL) 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DECAN 4 ONE; CHLORDIAZEPOXIDE; DIAZEPAM; NOCICEPTIN RECEPTOR;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; EXPERIMENTAL TEST; FEMALE; FOOTSHOCK; FORCED SWIMMING TEST; HOPELESSNESS; MALE; MOUSE; NONHUMAN; NOVELTY INDUCED HYPOPHAGIA TEST; PRIORITY JOURNAL; RAT; SOCIAL APPROACH AVOIDANCE TEST; STRESS INDUCED HYPERTHERMIA TEST; TAIL SUSPENSION TEST; TRANQUILIZING ACTIVITY; VOGEL CONFLICT PUNISHED DRINKING TEST;

EID: 85027958364     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2636-x     Document Type: Article

References (76)

1. Adriaan Bouwknecht J, Olivier B, Paylor RE (2007) The stressinduced hyperthermia paradigm as a physiological animal model for anxiety: A review of pharmacological and genetic studies in the mouse. Neurosci Biobehav Rev 31:41-59
2. Basso AM, Gallagher KB, Mikusa JP, Rueter LE (2011) Vogel conflict test: Sex differences and pharmacological validation of the model. Behav Brain Res 218:174-83
3. Bongsebandhu-phubhakdi S, Manabe T (2007) The neuropeptide nociceptin is a synaptically released endogenous inhibitor of hippocampal long-term potentiation. J Neurosci 27:4850-8
4. Cavallini S, Marino S, Beani L, Bianchi C, Siniscalchi A (2003) Nociceptin inhibition of acetylcholine efflux from different brain areas. Neuroreport 14:2167-70
5. Chee MJ, Price CJ, Statnick MA, Colmers WF (2011) Nociceptin- orphanin F/Q suppresses the excitability of neurons in the ventromedial nucleus of the hypothalamus. J Physiol 589(Pt 13):3103-14
6. Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C, Prinssen EP (2007) Nociceptin/orphanin FQ peptide receptors: Pharmacology and clinical implications. Curr Drug Targets 8:117-35
7. Ciccocioppo R, Biondini M, Antonelli L, Wichmann J, Jenck F, Massi M (2002) Reversal of stress- and CRF-induced anorexia in rats by the synthetic nociceptin/orphanin FQ receptor agonist, Ro 64- 6198. Psychopharmacology (Berl) 161:113-9
8. Ciccocioppo R, Cippitelli A, Economidou D, Fedeli A, Massi M (2004) Nociceptin/orphanin FQ acts as a functional antagonist of corticotropin- releasing factor to inhibit its anorectic effect. Physiol Behav 82:63-8
9. Cryan JF, Holmes A (2005) The ascent of mouse: Advances in modelling human depression and anxiety. Nat Rev Drug Discov 4:775-90
10. Dautzenberg FM, Wichmann J, Higelin J, Py-Lang G, Kratzeisen C, Malherbe P, Kilpatrick GJ, Jenck F (2001) Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: Rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo. J Pharmacol Exp Ther 298:812-9
11. Dawe KL, Wakerley JB, Fulford AJ (2010) Nociceptin/orphanin FQ and the regulation of neuronal excitability in the rat bed nucleus of the stria terminalis: Interaction with glucocorticoids. Stress 13:516-27
12. Dulawa SC, Hen R (2005) Recent advances in animal models of chronic antidepressant effects: The novelty-induced hypophagia test. Neurosci Biobehav Rev 29:771-83
13. Duzzioni M, Duarte FS, Leme LR, Gavioli EC, De Lima TC (2011) Anxiolytic-like effect of central administration of NOP receptor antagonist UFP-101 in rats submitted to the elevated T-maze. Behav Brain Res 222:206-211
14. Economidou D, Fedeli A, Martin Fardon R, Weiss F, Massi M, Ciccocioppo R (2006) Effect of novel nociceptin/orphanin FQ- NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats. Peptides 27:3299-3206
15. Fernandez F, Misilmeri MA, Felger JC, Devine DP (2004) Nociceptin/ orphanin FQ increases anxiety-related behavior and circulating levels of corticosterone during neophobic tests of anxiety. Neuropsychopharmacology 29:59-71
16. File SE (1991) The biological basis of anxiety. In:Meltzer HY, Nerozzi D (eds) Current practices and the future developments in the pharmacotherapy of mental disorders. Elsevier, Amsterdam, pp 159-165
17. Fornari RV, Soares JC, Ferreira TL, Moreira KM, Oliveira MG (2008) Effects of nociceptin/orphanin FQ in the acquisition of contextual and tone fear conditioning in rats. Behav Neurosci 122:98-106
18. Friedman BH (2007) An autonomic flexibility-neurovisceral integration model of anxiety and cardiac vagal tone. Biol Psychol 74:185-99
19. Gavioli EC, Calo G (2006) Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands. Naunyn Schmiedebergs Arch Pharmacol 372:319-30
20. Gavioli EC, Marzola G, Guerrini R, Bertorelli R, Zucchini S, De Lima TC, Rae GA, Salvadori S, Regoli D, Calo G (2003) Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: Pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci 17:1987-90
21. Gavioli EC, Rizzi A, Marzola G, Zucchini S, Regoli D, Calo G (2007) Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice. Peptides 28:1229-39
22. Gavioli EC, Vaughan CW, Marzola G, Guerrini R, Mitchell VA, Zucchini S, De Lima TC, Rae GA, Salvadori S, Regoli D, Calo G (2004) Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: New evidence from rats and mice. Naunyn Schmiedebergs Arch Pharmacol 369:547-53
23. Goeldner C, Reiss D, Kieffer BL, Ouagazzal AM (2010) Endogenous nociceptin/orphanin-FQ in the dorsal hippocampus facilitates despair-related behavior. Hippocampus 20:911-6
24. Goeldner C, Reiss D, Wichmann J, Kieffer BL, Ouagazzal AM (2009) Activation of nociceptin opioid peptide (NOP) receptor impairs contextual fear learning in mice through glutamatergic mechanisms. Neurobiol Learn Mem 91:393-401
25. Goeldner C, Reiss D, Wichmann J, Meziane H, Kieffer BL, Ouagazzal AM (2008) Nociceptin receptor impairs recognition memory via interaction with NMDA receptor-dependent mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in the hippocampus. J Neurosci 28:2190-8
26. Griebel G, Perrault G, Sanger DJ (1999) Orphanin FQ, a novel neuropeptide with anti-stress-like activity. Brain Res 836:221-4
27. Groenink L, van der Gugten J, Zethof T, van der Heyden J, Olivier B (1994) Stress-induced hyperthermia in mice: Hormonal correlates. Physiol Behav 56:747-9
28. Haller J, Bakos N (2002) Stress-induced social avoidance: A new model of stress-induced anxiety? Physiol Behav 77:327-32
29. Higgins GA, Grottick AJ, Ballard TM, Richards JG,Messer J, Takeshima H, Pauly-Evers M, Jenck F, Adam G,Wichmann J (2001) Influence of the selective ORL1 receptor agonist, Ro64-6198, on rodent neurological function. Neuropharmacology 41:97-107
30. Higgins GA, Kew JN, Richards JG, Takeshima H, Jenck F, Adam G, Wichmann J, Kemp JA, Grottick AJ (2002) A combined pharmacological and genetic approach to investigate the role of orphanin FQ in learning and memory. Eur J Neurosci 15:911-22
31. Hirao A, Imai A, Sugie Y, Tamura T, Shimokawa H, Toide K (2008a) Pharmacological properties of a novel nociceptin/orphanin FQ receptor agonist, 2-(3,5-dimethylpiperazin-1-yl)-1-[1-(1-methylcyclooctyl) piperidin-4-yl]-1H- benzimidazole, with anxiolytic potential. Eur J Pharmacol 579:189-95
32. Hirao A, Imai A, Sugie Y, Yamada Y, Hayashi S, Toide K (2008b) Pharmacological characterization of the newly synthesized nociceptin/ orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4- piperidinyl]-2-[(3R)-3- piperidinyl]-1H-benzimidazole as an anxiolytic agent. J Pharmacol Sci 106:361-8
33. Jenck F, Moreau JL, Martin JR, Kilpatrick GJ, Reinscheid RK, Monsma FJ Jr, Nothacker HP, Civelli O (1997) Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc Natl Acad Sci U S A 94:14854-8
34. Jenck F, Ouagazzal AM, Pauly-EversM,Moreau JL (2000a) OrphaninFQ: Role in behavioral fear responses and vulnerability to stress? Mol Psychiatry 5:572-4
35. Jenck F, Wichmann J, Dautzenberg FM, Moreau JL, Ouagazzal AM, Martin JR, Lundstrom K, Cesura AM, Poli SM, Roever S, Kolczewski S, Adam G, Kilpatrick G (2000b) A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: Anxiolytic profile in the rat. Proc Natl Acad Sci U S A 97:4938-43
36. Kamei J, Matsunawa Y, Miyata S, Tanaka S, Saitoh A (2004) Effects of nociceptin on the exploratory behavior of mice in the hole-board test. Eur J Pharmacol 489:77-87
37. Kawahara Y, Hesselink MB, van Scharrenburg G, Westerink BH (2004) Tonic inhibition by orphanin FQ/nociceptin of noradrenaline neurotransmission in the amygdala. Eur J Pharmacol 485:197-200
38. Klein S, Nicolas LB, Lopez-Lopez C, Jacobson LH, McArthur SG, Grundschober C, Prinssen EP (2010) Examining face and construct validity of a noninvasive model of panic disorder in Lister-hooded rats. Psychopharmacology (Berl) 211:197-208
39. Ko MC, Woods JH, Fantegrossi WE, Galuska CM, Wichmann J, Prinssen EP (2009) Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology 34:2088-96
40. Kuzmin A, Madjid N, Johansson B, Terenius L, Ogren SO (2009) The nociceptin system and hippocampal cognition in mice: A pharmacological and genetic analysis. Brain Res 1305(Suppl):S7-19
41. Lambert DG (2008) The nociceptin/orphanin FQ receptor: A target with broad therapeutic potential. Nat Rev Drug Discov 7:694-710
42. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, Jones RM, Portoghese PS, CarlezonWA Jr (2003) Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305:323-30
43. Manabe T, Noda Y, Mamiya T, Katagiri H, Houtani T, Nishi M, Noda T, Takahashi T, Sugimoto T, Nabeshima T, Takeshima H (1998) Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors. Nature 394:577-81
44. McLeod RL, Jia Y, Fernandez X, Parra LE, Wang X, Tulshian DB, Kiselgof EJ, Tan Z, Fawzi AB, Smith-Torhan A, Zhang H, Hey JA (2004) Antitussive profile of the NOP agonist Ro-64-6198 in the guinea pig. Pharmacology 71:143-9
45. McNaughton N, Corr PJ (2004) A two-dimensional neuropsychology of defense: Fear/anxiety and defensive distance. Neurosci Biobehav Rev 28:285-305
46. Meis S (2003) Nociceptin/orphanin FQ: Actions within the brain. Neuroscientist 9:158-68
47. Meunier JC (1997) Nociceptin/orphanin FQ and the opioid receptorlike ORL1 receptor. Eur J Pharmacol 340:1-15
48. Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83-244
49. Mollereau C, Mouledous L (2000) Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides 21:907-17
50. Neal CR Jr, Mansour A, Reinscheid R, Nothacker HP, Civelli O, Akil H, Watson SJ Jr (1999) Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: Comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding. J Comp Neurol 412:563-605
51. Nicolas LB, Klein S, Prinssen EP (2007) Defensive-like behaviors induced by ultrasound: Further pharmacological characterization in Lister-hooded rats. Psychopharmacology (Berl) 194:243-52
52. Nicolas LB, Kolb Y, Prinssen EP (2006) A combined marble buryinglocomotor activity test in mice: A practical screening test with sensitivity to different classes of anxiolytics and antidepressants. Eur J Pharmacol 547:106-15
53. Nicolas LB, Prinssen EP (2006) Social approach-avoidance behavior of a high-anxiety strain of rats: Effects of benzodiazepine receptor ligands. Psychopharmacology (Berl) 184:65-74
54. Obara I, Przewlocki R, Przewlocka B (2005) Spinal and local peripheral antiallodynic activity of Ro64-6198 in neuropathic pain in the rat. Pain 116:17-25
55. Olivier B, Zethof T, Pattij T, van Boogaert M, van Oorschot R, Leahy C, Oosting R, Bouwknecht A, Veening J, van der Gugten J, Groenink L (2003) Stress-induced hyperthermia and anxiety: Pharmacological validation. Eur J Pharmacol 463:117-32
56. Olszewski PK, Levine AS (2004) Minireview: Characterization of influence of central nociceptin/orphanin FQ on consummatory behavior. Endocrinology 145:2627-32
57. Ramos A (2008) Animal models of anxiety: Do I need multiple tests? Trends Pharmacol Sci 29:493-8
58. Recker MD, Higgins GA (2004) The opioid receptor like-1 receptor agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-hexahydro-1H-phenalen- 1-yl-1-phenyl-1,3,8- triaza-sp iro[4.5]decan-4-one) produces a discriminative stimulus in rats distinct from that of a mu, kappa, and delta opioid receptor agonist cue. J Pharmacol Exp Ther 311:652-8
59. Redrobe JP, Calo G, Regoli D, Quirion R (2002) Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. Naunyn Schmiedebergs Arch Pharmacol 365:164-7
60. Reinscheid RK (2006) The Orphanin FQ / Nociceptin receptor as a novel drug target in psychiatric disorders. CNS Neurol Disord Drug Targets 5:219-24
61. Reiss D, Wichmann J, Tekeshima H, Kieffer BL, Ouagazzal AM (2008) Effects of nociceptin/orphanin FQ receptor (NOP) agonist, Ro64-6198, on reactivity to acute pain in mice: Comparison to morphine. Eur J Pharmacol 579:141-8
62. Rizzi A, Gavioli EC, Marzola G, Spagnolo B, Zucchini S, Ciccocioppo R, Trapella C, Regoli D, Calo G (2007) Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB- 612111 [(-)-cis-1-methyl-7-[[4- (2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9 -tetrahydro-5H- benzocyclohepten-5-ol]: In vivo studies. J Pharmacol Exp Ther 321:968-74
63. Rizzi A, Molinari S, Marti M, Marzola G, Calo G (2011) Nociceptin/ orphanin FQ receptor knockout rats: In vitro and in vivo studies. Neuropharmacology 60:572-9
64. Schlicker E, Morari M (2000) Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system. Peptides 21:1023-9
65. Sclafani A (2006) Enhanced sucrose and polycose preference in sweet "sensitive" (C57BL/6J) and "subsensitive" (129P3/J) mice after experience with these saccharides. Physiol Behav 87:745-56
66. Shoblock JR (2007) The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity. CNS Drug Rev 13:107-36
67. Spooren WP, Schoeffter P, Gasparini F, Kuhn R, Gentsch C (2002) Pharmacological and endocrinological characterisation of stressinduced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur J Pharmacol 435:161-70
68. Tomasiewicz HC, Mague SD, Cohen BM, Carlezon WA Jr (2006) Behavioral effects of short-term administration of lithium and valproic acid in rats. Brain Res 1093:83-94
69. Varty GB, Hyde LA, Hodgson RA, Lu SX, McCool MF, Kazdoba TM, Del Vecchio RA, Guthrie DH, Pond AJ, Grzelak ME, Xu X, Korfmacher WA, Tulshian D, Parker EM, Higgins GA (2005) Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species. Psychopharmacology (Berl) 182:132-43
70. Varty GB, Lu SX, Morgan CA, Cohen-Williams ME, Hodgson RA, Smith-Torhan A, Zhang H, Fawzi AB, Graziano MP, Ho GD, Matasi J, Tulshian D, Coffin VL, Carey GJ (2008) The anxiolyticlike effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo [3.2.1]octan-3-ol (SCH 221510). J Pharmacol Exp Ther 326:672-82
71. Veening JG, Bouwknecht JA, Joosten HJ, Dederen PJ, Zethof TJ, Groenink L, van der Gugten J, Olivier B (2004) Stress-induced hyperthermia in the mouse: C-fos expression, corticosterone and temperature changes. Prog Neuropsychopharmacol Biol Psychiatry 28:699-707
72. Vinkers CH, van Bogaert MJ, Klanker M, Korte SM, Oosting R, Hanania T, Hopkins SC, Olivier B, Groenink L (2008) Translational aspects of pharmacological research into anxiety disorders: The stress-induced hyperthermia (SIH) paradigm. Eur J Pharmacol 585:407-25
73. Vitale G, Arletti R, Ruggieri V, Cifani C, Massi M (2006) Anxiolyticlike effects of nociceptin/orphanin FQ in the elevated plus maze and in the conditioned defensive burying test in rats. Peptides 27:2193-200
74. Vitale G, Ruggieri V, Filaferro M, Frigeri C, Alboni S, Tascedda F, Brunello N, Guerrini R, Cifani C, Massi M (2009) Chronic treatment with the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats. Psychopharmacology (Berl) 207:173-89
75. Wei WZ, Xie CW (1999) Orphanin FQ suppresses NMDA receptordependent long-term depression and depotentiation in hippocampal dentate gyrus. Learn Mem 6:467-77
76. Wichmann J, Adam G, Rover S, Hennig M, Scalone M, Cesura AM, Dautzenberg FM, Jenck F (2000) Synthesis of (1S,3aS)-8- (2,3,3a,4,5, 6-hexahydro-1H- phenalen-1-yl)-1-phenyl-1,3,8-triaza- spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties. Eur J Med Chem 35:839-51